Pamela Sutherland v. DCC Litig. Facility, Inc.

• Court: Court of Appeals for the Sixth Circuit
• Decided: June 27, 2024
• Docket: 23-1976
• Status: Unpublished

Opinion

NOT RECOMMENDED FOR PUBLICATION File Name: 24a0281n.06

Case No. 23-1976

UNITED STATES COURT OF APPEALS FILED FOR THE SIXTH CIRCUIT Jun 27, 2024 KELLY L. STEPHENS, Clerk

) PAMELA D. SUTHERLAND, ) ON APPEAL FROM THE Plaintiff-Appellant, ) UNITED STATES DISTRICT ) COURT FOR THE EASTERN v. ) DISTRICT OF MICHIGAN ) DCC LITIGATION FACILITY, INC., ) OPINION Defendant-Appellee. ) )

Before: CLAY, McKEAGUE, and READLER, Circuit Judges.

PER CURIAM. In “one of the world’s largest mass tort litigations,” scores of women sued

Dow Corning claiming that its silicone breast implants caused their health problems. In re Dow

Corning Corp., 86 F.3d 482, 486 (6th Cir. 1996), as amended on denial of reh’g and reh’g en banc

(6th Cir. 1996).1 Hundreds of thousands ultimately joined in a class settlement. Id. at 485–86.

Others (still thousands) opted out and pressed separate lawsuits. Id. at 485.

Pamela Sutherland was one of those who opted out. But in the end, her claim failed. In

2016, the district court granted Dow summary judgment because it said Ms. Sutherland couldn’t

prove that Dow’s implants caused her injuries. Though she offered some proposed experts on that

issue, the court excluded them under Federal Rule of Evidence 702 as unreliable. Six years later,

1 We have explained the factual background of these cases in many other published and unpublished opinions. See, e.g., In re Dow Corning Corp., 778 F.3d 545, 547–48 (6th Cir. 2015); Gatza v. DCC Litig. Facility, Inc., 717 F. App’x 519, 520 (6th Cir. 2017). We recount only basic facts here. No. 23-1976, Sutherland v. DCC Litigation Facility, Inc.

Ms. Sutherland asked the court to alter, amend, or provide relief from that judgment under Federal

Rules of Civil Procedure 59(e), 60(b)(2), 60(b)(3), and 60(b)(6). She also requested a “final

accounting” of the settlement. R.128 at PageID 6387. She thought that relief was appropriate

because (1) the United States Food and Drug Administration had recently found cancer “in the

scar tissue of silicone breast implants,” and (2) information suggested that Dow never fully paid

the class settlement. Id. at 6388.

The district court denied Ms. Sutherland’s requests for three reasons. One: her motions

under Rules 59(e), 60(b)(2), and 60(b)(3) were all untimely. Ms. Sutherland had only 28 days to

file her motion under Rule 59(e) and one year under the others. Two: she had not shown

exceptional or extraordinary circumstances, as required by Rule 60(b)(6). See R.138 at

PageID 6480 (citing Buck v. Davis, 580 U.S. 100, 123 (2017), and Olle v. Henry & Wright Corp.,

910 F.2d 357, 365 (6th Cir. 1990)). Three: she was not entitled to an accounting concerning the

settlement because she had opted out.

Ms. Sutherland appeals that ruling. She doesn’t, however, explain where it went wrong.

She instead repeats her theory as to why she believes Dow shorted the settlement class’s payout

and cites next to no legal authority. Particularly given the fact that she is represented by counsel,

her failure to substantively address the district court’s analysis is fatal to her appeal. See United

States v. Rich, Nos. 18-2268 et al., 2021 WL 4144059, at *40 (6th Cir. Sept. 13, 2021); Vander

Boegh v. EnergySolutions, Inc., 772 F.3d 1056, 1063 (6th Cir. 2014). But even if we put that

oversight aside, we don’t see any grounds to reverse. The district court correctly described the

applicable law and properly applied it to the facts.

We affirm.